TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
35 hedge funds and large institutions have $25.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 12 closing their positions.
328% more call options, than puts
Call options by funds: $826K | Put options by funds: $193K
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
20% less funds holding
Funds holding: 44 → 35 (-9)
35% less capital invested
Capital invested by funds: $39M → $25.4M (-$13.7M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.71M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$62.9K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$47.9K |
| 4 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$38K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$3.04M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$556K |
| 3 |
Millennium Management
New York
|
-$540K |
| 4 |
Two Sigma Investments
New York
|
-$381K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$333K |
TCON Hedge Fund Activity: Q4 2021 in Review
35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2021, worth a combined $25.4M — down 35% from $39M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TCON and 3 opened new positions — a net loss of 9 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Opaleye Management, adding an estimated $1.71M. The largest seller was Altium Capital Management, exiting entirely with an estimated $3.04M sold.
- 35 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2021, down from 44 in Q3 2021.
- Funds reported $25.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 35% quarter-over-quarter.
- 3 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of -9 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Opaleye Management, an estimated $1.71M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Altium Capital Management, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2021.